Agios Pharmaceuticals, Inc. has announced impressive financial results for the third quarter of 2026, showcasing a substantial increase in revenue driven by its innovative treatment for thalassemia, AQVESME. The company reported worldwide net revenues of $55.4 million for the quarter, a remarkable increase from $12.9 million in the same period last year. This growth reflects strong U.S. demand and positions Agios favorably in the competitive pharmaceutical preparations industry.
On November 5, 2026, Agios Pharmaceuticals issued a press release detailing its financial performance for the quarter ended September 30, 2026. The results indicate that the company has not only surpassed its previous year's revenue but also established a solid foundation for future growth.
Background
Agios Pharmaceuticals, Inc. (Nasdaq: AGIO) is a commercial-stage biopharmaceutical company based in Cambridge, Massachusetts, focused on delivering innovative medicines for patients with rare diseases. The company operates under the Standard Industrial Classification (SIC) code 2834, which pertains to pharmaceutical preparations. Agios has been actively filing reports with the SEC, with its most recent filings including an 8-K on November 5, 2026, and several other forms throughout October 2026.
What the Filing Says
The filing revealed that Agios's net revenues from its product, mitapivat (marketed as AQVESME), reached $55.4 million in the third quarter of 2026, significantly up from $12.9 million in the same quarter of 2025. The press release stated, "The third quarter was a record for our product revenue, outperforming our entire 2025 total in just three months." This growth was attributed to the U.S. commercial launch of AQVESME in thalassemia, which has seen increasing demand.
Additionally, Agios reported that as of September 30, 2026, there were 619 cumulative prescriptions for AQVESME from REMS-certified physicians, indicating a strong uptake in the market. The company is also preparing for a new PDUFA goal date for mitapivat's supplemental New Drug Application (sNDA) for sickle cell disease, set for February 1, 2027.
Impact
The financial results and updates provided by Agios may significantly impact various stakeholders, including healthcare providers, patients, and investors. The strong performance of AQVESME in the thalassemia market positions Agios as a competitive player in the pharmaceutical industry, particularly in the rare hematology segment. Furthermore, the upcoming FDA review for sickle cell disease could open new avenues for growth and market expansion.
What's Next
The filing does not specify what happens next, but the upcoming FDA review for the sickle cell disease indication is a critical milestone for Agios. The company is also likely to continue focusing on its commercial strategy for AQVESME and prepare for potential future product launches.
Read Next
Ronald N. Tutor sells 150,000 shares of Tutor Perini Corp.
Generation Income Properties reports Q3 2026 results
Greenlane Holdings reports Q3 2026 results amid challenges
Permianville Royalty Trust Reports Q3 Financial Results
Cue Biopharma Reports Q3 Results with Financial Insights
Atlantica Inc Reports Q3 Results, Highlights Financial Updates










